Medigen Vaccine Biologics Corp (高端疫苗) has applied to Paraguay’s National Health Monitoring Directorate to conduct phase 3 clinical trials for its COVID-19 experimental vaccine in the country, the company said in a filing with the Taipei Exchange (TPEX) on Tuesday.
The company would collaborate with the National University of Asuncion in Paraguay to conduct phase 3 clinical trials in a university-affiliated hospital, the filing said.
After discussions with the Paraguayan regulator, the vaccine maker said that it would adopt immunobridging to compare the overall level of protection provided by its vaccine candidate with that of the AstraZeneca COVID-19 vaccine.
Photo courtesy of the Presidential Office via AP
Immunobridging is a means of inferring a vaccine’s efficacy by comparing the immune response of participants given an approved vaccine with the response of others given the experimental vaccine.
Conducting the phase 3 clinical trials in Paraguay and registering its COVID-19 vaccine in the country would help Medigen gain a foothold in the markets of Central and South America, it said.
The company said that it is also in talks with EU regulators, as it plans to conduct phase 3 clinical trials in other markets.
Medigen on Tuesday did not disclose how many participants would be enrolled in the trials in Paraguay, the time frame for completing the trials or their cost.
Medigen chief executive officer Charles Chen (陳燦堅) told a news conference last month that the company had considered recruiting about 30,000 participants for the phase 3 clinical trials.
Phase 2 clinical trials for the vaccine, which were completed on June 9, raised no major safety concerns, the company said, adding that the data on the generation of neutralizing antibodies were generally well-received.
On June 15, Medigen said that it applied to the Food and Drug Administration (FDA) for emergency use authorization for the vaccine.
In related news, UBI Pharma Inc (聯亞藥) last month said that its US-based affiliate, Vaxxinity, had signed a contract with the Paraguayan government to supply 1 million doses of its COVID-19 vaccine.
“So far neither we nor our parent company, United Biomedical Inc (聯亞生技), have been assigned to produce the 1 million doses,” UBI Pharma said in a TPEX filing.
United Biomedical is another local company working on the development of a COVID-19 vaccine and has also applied to the FDA for emergency use authorization of its vaccine candidate, UB-612, after releasing interim results from its phase 2 clinical trials.
The company aims to begin phase 3 clinical trials in India with 11,000 participants.
Facebook Inc on Wednesday reported its profit doubled in the second quarter as digital advertising surged, but warned of cooler growth in the months ahead in an update that sent its shares sinking. Profit rose to US$10.4 billion on revenue of US$29 billion, a 56 percent increase from last year, mainly from an increase in ad revenue, Facebook said. The number of people using the social network monthly climbed to 2.9 billion, a year-on-year gain of 7 percent, while about 3.5 billion people used at least one of the company’s apps, including Instagram, WhatsApp and Messenger. “We had a strong quarter, as we
FURTHER TAX MEASURES NEEDED? Corporate owners accounted for almost 30 percent of empty houses, many of which are held by firms that own 10 or more properties The number of unoccupied houses nationwide totaled 876,000 units last year, or 11.94 percent of all houses, the Ministry of the Interior said in a report issued on Thursday. Almost 30 percent of empty houses were owned by companies, suggesting that many corporate property owners engage in house hoarding, the ministry said. Excluding developers and builders, companies still owned 20 percent of empty houses, it said. The report is based on housing units’ electricity use and considers properties that use less than 60 kilowatt-hours per month as unoccupied. The study contradicts Ministry of Finance reports saying that house hoarding subsided and there is no
HIGH-END MARKET: The company has sufficient growth upsides in its four major business segments to reach revenue of US$20 billion, CEO Rick Tsai told investors MediaTek Inc (聯發科), the world’s biggest supplier of 5G smartphone chips, yesterday raised its revenue growth target for this year to more than 45 percent, after strong demand mainly for its mid-range and premium 5G chips pushed net profit to a record high last quarter. The Hsinchu-based chip designer had three months earlier projected a 40 percent growth from NT$322.16 billion (US$11.48 billion) last year. MediaTek expects next year to be another growth year, with a higher 5G penetration rate and accelerating digital transformation during the post-COVID-19 pandemic era. The company also gained confidence about its gross margin improvement on the expectation
CAUSE INVESTIGATED: The incident occurred early in the morning, when electricity demand was low, and did not result in a power outage or a radiation leak, Taipower said The No. 2 reactor at the Guosheng Nuclear Power Plant in New Taipei City’s Wanli District (萬里) experienced a malfunction that triggered an automatic shutdown early yesterday morning, Taiwan Power Co (Taipower, 台電) said. The exact cause of the incident is still being investigated, but there is no risk of a radiation leak, the state-run utility said. “While we are still investigating the exact cause, the automatic shutdown was safely executed and there is no danger from radiation,” Taipower spokesman Chang Ting-shu (張廷舒) said. The malfunction occurred at 6:33am, triggering an emergency shutdown, taking 985 megawatts of power offline, Chang said. The control